PT-141 (Bremelanotide) Dosage Guide
Complete guide to PT-141 (Bremelanotide) dosing protocols, administration methods, and safety considerations for research purposes.
NOT Medical Advice
The dosage and calculator information provided is for educational and research purposes only. Peptides are not approved by the FDA for human use. Individual responses vary significantly. Always consult with a qualified healthcare professional before making any decisions related to peptide research or use.
Dosage Overview
Dose Range
1.8 mg
Route
subcutaneous
Frequency
Weekly
Cycle Length
4-12 weeks
Reconstitution
Vial Size
10 mg
BAC Water
2.0 ml
Concentration
5,000 mcg/ml
Detailed Dosage Information
FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month.
Administration Method
Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols.
Research Use Only: All dosage ranges and calculations are derived from published research literature and are provided for educational purposes. These are not prescriptions or medical recommendations. Consult a healthcare professional before any use.
Quick Calculator
Concentration: 5,000 mcg/ml
Volume to inject: 0.35 ml
Syringe units (U-100): 35.0 units
Pre-filled with PT-141 (Bremelanotide) defaults. Adjust values as needed.
Side Effects to Monitor
Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur.
Safety Considerations & Risks
Not recommended for use with alcohol. May cause significant nausea. Should not be used in patients with uncontrolled hypertension or cardiovascular disease.